This website uses cookies to improve your experience.

Cookie policy

Chemotherapy with or without algenpantucel-L (HyperAcute-Pancreas) immunotherapy in subjects with borderline resectable or locally advanced unresectable pancreatic cancer.


Hewitt, DB, Nissen N, Hatoum H, Musher B, Seng J, Coveler AL et al.
Ann Surg 2022; 275: 45-53.

In this study that included 303 patients, the addition of neoadjuvant immunotherapy did not improve progression-free survival (12. versus 13.4 months in controls) or overall survival (14.3 versus 14.9 months, respectively).

Comment: disappointing negative result.

Read paper

Academy


Part of the charitable activity of the Foundation, BJS Academy is an online educational resource for current and future surgeons.

The Academy is comprised of five distinct sections: Continuing surgical education, Young BJS, Cutting edge, Scientific surgery and Surgical news. Although the majority of this is open access, additional content is available to BJS subscribers and strategic partners.

Discover the Academy
Surgeon Training & Surgeons in Surgery